Archive for November, 2009

The WHO recommends a vaccination scheme against influenza A at a dose to the whole population

Sunday, November 1st, 2009

The World Health Organization (WHO) recommended Friday (October 30) during a press conference call a scheme vaccine against influenza A (H1N1) at a dose with products certified for all subjects aged over of 6 months.
She also called for the administration of any type of licensed vaccine against influenza A (H1N1), adjuvanted or not, pregnant women, as well as the general possibility of co-administer the vaccine against influenza A ( H1N1) simultaneously with that against seasonal influenza.
These recommendations are based on those issued by the Strategic Advisory Group of Experts on immunization (SAGE), an independent expert committee on immunization with the WHO, which met on Wednesdays only the issue of vaccination against Influenza A (H1N1) and has updated its recommendations issued in July, said Dr. Marie-Paule Kieny, Director of the Initiative for Vaccine Research at WHO.
On the issue of immunization schedule, the specialist said that experts had examined the clinical trials, as well as the decisions and recommendations of the national authorities.
They decided to recommend a dose for all subjects older than 6 months, with the live attenuated vaccine, inactivated, adjuvant or not, and especially those of GlaxoSmithKline (Pandemrix *) and Novartis (Focetria *) on the database “of immune response and public health considerations,” she said. (more…)

Difficulties of treatment of arterial wounds

Sunday, November 1st, 2009

The occurrence of an ulcer of arterial origin evidence the existence of severe ischemia which may lead to a mutation.
The arterial lesions are usually localized at the axis of femoral-popliteal and leg arteries. So to the clinical examination the femoral pulse is generally well perceived and pulse not found downstream.
We must differentiate between ulcers of the forefoot that once the bypass performed at worst lead to amputation limited type trans-metatarsal ulcers of the hindfoot. (more…)

Bilirubin

Sunday, November 1st, 2009

Substance normally present in blood and coming for 80 to 85% from hemoglobin in red blood cells and when these, after 120 days on average, arrive at the end of their useful lives are destroyed in the spleen and the heme in hemoglobin is converted in bilirubin.
An other dimension is, 10-15% is produced directly from bone marrow during a process of ineffective erythropoiesis, while the remaining 5% is formed in the liver and is then poured into the intestine.
Bilirubin is a substance to move so poorly soluble in an aqueous medium such as blood plasma, requires a carrier which turns out to be albumin.
This is called indirect bilirubin, and is the type that is more in the blood, while those that produced by the liver and is soluble in water. (more…)